Regulatory and Economic Aspects in Oncology

  • Korchagina D
  • Jaroslawski S
  • Jadot G
  • et al.
N/ACitations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Description based upon print version of record. 4.5 The Institute for Clinical and Economic Review Value Assessment Framework Intro; Contents; About the Editor; 1 Introduction and Overview; Abstract; References; 2 Cost of Cancer: Healthcare Expenditures and Economic Impact; Abstract; 1 Introduction; 2 Methods; 3 Total Health Expenditures on Cancer; 4 Spending on Cancer Drugs; 5 Resource Use Outside the Healthcare Sector for Care of Cancer Patients; 6 Resources Lost Due to Economic Impact on Persons with Cancer; 7 Loss of Health in Economic Terms; 8 Summary and Conclusions; References; 3 Oncology from an HTA and Health Economic Perspective; Abstract; 1 Introduction 2 Brief Overview of Cost-Effectiveness Models in Oncology3 Issue with Clinical Inputs Due to Crossover (Switch) in Randomised Clinical Trials; 4 Need for Survival Extrapolation and Limitations with Current Parametric Model; 5 Rare Indications with Limited Economic and Comparative Evidence Available; 6 High Pace of Clinical Development; 7 Further Issues with Health Economic Models in Oncology; 7.1 Health-Related Quality of Life; 8 Comparator and Off-Label; 9 Cost-Effectiveness Vs Affordability; 10 Conclusion; References 4 Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative AssessmentAbstract; 1 Introduction; 2 Brief Overview of Selected HTA Agencies; 2.1 France-HAS; 2.2 Germany-IQWiG/G-BA; 2.3 UK-England-NICE; 2.4 UK-Scotland-SMC; 2.5 Sweden; 2.6 Australia; 2.7 Canada; 3 Comparison of HTA Decision-Making Frameworks; 3.1 HTA Outcomes; 3.2 HTA Aspects Specific to Oncology; 4 Evaluation Criteria and Processes in HTA; 4.1 Cross-Country Comparison of HTA Recommendations in Oncology; 5 Conclusion; References 5 Patient-Reported Outcomes in Oncology, Beyond Randomized Controlled TrialsAbstract; 1 Introduction; 2 Patient Perspective Differs from HealthCare Professional Perspective; 3 Definition of PROs and Classification; 4 PROs in Oncology Clinical Trials; 5 Validity of PRO Instruments; 6 Other Methods to Capture Patient's Perspectives; 7 Value of PRO in Oncology; References; 6 Patient-Reported Outcomes in Health Economic Decision-Making: A Changing Landscape in Oncology; Abstract; 1 Introduction; 2 Global Oncology Snapshot; 3 Reframing the Value Equation 4 Patient-Centered Care and Patient-Reported Outcomes5 Investments in PRO Measures; 6 Challenges and Potential Solutions; 7 Conclusion; References; 7 Approaches to Capturing Value in Oncology; Abstract; 1 Introduction; 2 Value-An Ambiguous Concept; 3 Quality-Adjusted Life Years (QALY) and ICERs Core Metrics; 4 The Five Value Frameworks; 4.1 The ESMO Magnitude of Clinical Benefit Scale; 4.2 The American Society of Clinical Oncology (ASCO) Value Framework; 4.3 National Comprehensive Cancer Network Evidence Blocks; 4.4 Memorial Sloan Kettering Cancer Center DrugAbacus

Cite

CITATION STYLE

APA

Korchagina, D., Jaroslawski, S., Jadot, G., & Toumi, M. (2019). Regulatory and Economic Aspects in Oncology. (E. Walter, P. Schlag, & S. Hans-jörg, Eds.) (Vol. 213, p. 30543013). Springer International Publishing. https://doi.org/10.1007/978-3-030-01207-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free